A review of therapies for diabetic macular oedema and rationale for combination therapy

被引:49
作者
Amoaku, W. M. K. [1 ]
Saker, S. [1 ]
Stewart, E. A. [1 ]
机构
[1] Univ Nottingham, Acad Ophthalmol, Div Clin Neurosci, Queens Med Ctr, Nottingham NG7 2UH, England
关键词
ENDOTHELIAL GROWTH-FACTOR; DEXAMETHASONE INTRAVITREAL IMPLANT; JUNCTIONAL ADHESION MOLECULE; GRID LASER PHOTOCOAGULATION; ANGIOPOIETIN RECEPTOR TIE-2; RANDOMIZED CONTROLLED-TRIAL; HIGH GLUCOSE-CONCENTRATIONS; BLOOD-RETINAL BARRIER; DRUG-DELIVERY SYSTEM; VASCULAR-PERMEABILITY;
D O I
10.1038/eye.2015.110
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Diabetic macular oedema (DMO) is responsible for significant visual impairment in diabetic patients. The primary cause of DMO is fluid leakage resulting from increased vascular permeability through contributory anatomical and biochemical changes. These include endothelial cell (EC) death or dysfunction, pericyte loss or dysfunction, thickened basement membrane, loss or dysfunction of glial cells, and loss/change of EC Glycocalyx. The molecular changes include increased reactive oxygen species, pro-inflammatory changes: advanced glycation end products, intracellular adhesion molecule-1, Complement 5-9 deposition and cytokines, which result in increased paracellular permeability, tight junction disruption, and increased trans-cellular permeability. Laser photocoagulation has been the mainstay of treatment until recently when pharmacological treatments were introduced. The current treatments for DMO target reducing vascular leak in the macula once it has occurred, they do not attempt to treat the underlying pathology. These pharmacological treatments are aimed at antagonising vascular endothelial growth factor (VEGF) or non-VEGF inflammatory pathways, and include intravitreal injections of anti-VEGFs (ranibizumab, aflibercept or bevacizumab) or steroids (fluocinolone, dexamethasone or triamcinolone) as single therapies. The available evidence suggests that each individual treatment modality in DMO does not result in a completely dry macula in most cases. The ideal treatment for DMO should improve vision and improve morphological changes in the macular (eg, reduce macular oedema) for a significant duration, reduced adverse events, reduced treatment burden and costs, and be well tolerated by patients. This review evaluates the individual treatments available as monotherapies, and discusses the rationale and potential for combination therapy in DMO. A comprehensive review of clinical trials related to DMO and their outcomes was completed. Where phase III randomised control trials were available, these were referenced, if not available, phase II trials have been included.
引用
收藏
页码:1115 / 1130
页数:16
相关论文
共 149 条
[1]   Astrocyte-endothelial interactions at the blood-brain barrier [J].
Abbott, NJ ;
Rönnbäck, L ;
Hansson, E .
NATURE REVIEWS NEUROSCIENCE, 2006, 7 (01) :41-53
[2]  
Abraham RT, 2003, CURR TOP MICROBIOL, V279, P299
[3]   Is diabetic retinopathy an inflammatory disease? [J].
Adamis, AP .
BRITISH JOURNAL OF OPHTHALMOLOGY, 2002, 86 (04) :363-365
[4]   Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial [J].
Ahmadieh, Hamid ;
Ramezani, Alireza ;
Shoeibi, Nasser ;
Bijanzadeh, Bijan ;
Tabatabaei, Ali ;
Azarmina, Mohsen ;
Soheilian, Masoud ;
Keshavarzi, Gholamreza ;
Mohebbi, Mohammad-Reza .
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2008, 246 (04) :483-489
[5]   Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content - Vascular endothelial growth factor decreases occludin in retinal endothelial cells [J].
Antonetti, DA ;
Barber, AJ ;
Khin, S ;
Lieth, E ;
Tarbell, JM ;
Gardner, TW .
DIABETES, 1998, 47 (12) :1953-1959
[6]   Differential anti-inflammatory effects of immunosuppressive drugs:: Cyclosporin, rapamycin and FK-506 on inducible nitric oxide synthase, nitric oxide, cyclooxygenase-2 and PGE2 production [J].
Attur, MG ;
Patel, R ;
Thakker, G ;
Vyas, P ;
Levartovsky, D ;
Patel, P ;
Naqvi, S ;
Raza, R ;
Patel, K ;
Abramson, D ;
Bruno, G ;
Abramson, SB ;
Amin, AR .
INFLAMMATION RESEARCH, 2000, 49 (01) :20-26
[7]  
Beck RW, 2009, ARCH OPHTHALMOL-CHIC, V127, P245, DOI 10.1001/archophthalmol.2008.610
[8]   Diabetic Macular Edema: Pathogenesis and Treatment [J].
Bhagat, Neelakshi ;
Grigorian, Ruben A. ;
Tutela, Arthur ;
Zarbin, Marco A. .
SURVEY OF OPHTHALMOLOGY, 2009, 54 (01) :1-32
[9]   Diabetic retinopathy: The latest in current management [J].
Bhavsar, Abdhish R. .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2006, 26 (06) :S71-S79
[10]   25 years of progress in the treatment of retinal diseases: Where we have been, where we are now, and where we will be [J].
Bhavsar, Abdhish R. ;
Tornambe, Paul E. .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2006, 26 (06) :S1-S6